N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl.
AUTOR(ES)
Jackson, P
RESUMO
The two major forms of the c-abl gene differ from their activated counterpart, the v-abl oncogene of the Abelson murine leukemia virus by the replacement of their N-terminal sequences with viral gag sequences. Overexpression of p150c-abl type IV in a retroviral vector similar to Abelson virus does not transform NIH 3T3 fibroblasts, even though it is expressed and myristoylated at levels comparable to pp160v-abl. Members of a nested set of deletion mutations of the N-terminus of c-abl type IV in this expression system will activate abl to transform murine fibroblasts. The smallest of these deletions, delta XB, efficiently transforms lymphoid cells in vitro and causes leukemia in vivo demonstrating that gag sequences are not necessary for abl-induced leukemogenesis. The delta XB mutation defines an N-terminal regulatory domain, which shares a surprising homology with chicken oncogene v-crk and phospholipase C-II. Although overexpression of the myristoylated form of c-abl does not transform cells, it nonetheless has a profound effect on cell growth.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=400826Documentos Relacionados
- Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential.
- N-Myristoylated c-Abl Tyrosine Kinase Localizes to the Endoplasmic Reticulum upon Binding to an Allosteric Inhibitor*
- The murine AIDS virus Gag precursor protein binds to the SH3 domain of c-Abl.
- N-Terminal Mutations Modulate Yeast Snf1 Protein Kinase Function
- The N-terminal to C-terminal motif in protein folding and function